Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
150 participants
INTERVENTIONAL
2023-02-10
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cognitive Assessment and Brain Function Evaluation in Patients With Non-alcoholic Fatty Liver Disease
NCT05563259
The Liver Health Study for Patients with NAFLD
NCT03151798
A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes
NCT07241195
Visceral Adiposity and CVD Risk in Women
NCT00021879
Metabolic Subtypes of Non-Alcoholic Fatty Liver Disease
NCT05560997
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
non-contrast low-dose abdomen CT
non-contrast low-dose abdomen CT (target effective dose: \< 1.5 mSv). CT based body composition analysis is performedd with commercially available automatic segmentation software (DeepCatch, Medical IP, South Korea).
Non-contrast low-dose abdomen CT
target effective dose: \< 1.5 mSv It is performed twice in 6-month interval.
Fibroscan
Fibroscan is performed within a week of low-dose CT. It is used as a reference standard of hepatic fibrosis and steatosis.
bioelectrical impedance analysis (BIA)
BIA test is performed on the same day of low-dose CT. Commercially available model (Inbody 270) is used.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non-contrast low-dose abdomen CT
target effective dose: \< 1.5 mSv It is performed twice in 6-month interval.
Fibroscan
Fibroscan is performed within a week of low-dose CT. It is used as a reference standard of hepatic fibrosis and steatosis.
bioelectrical impedance analysis (BIA)
BIA test is performed on the same day of low-dose CT. Commercially available model (Inbody 270) is used.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* or non-alcoholic fatty liver disease with liver function test abnormality
* signed informed consent
Exclusion Criteria
* other disease related to fatty liver such as glycogen storage disease, lipodystrophy, familial combined hyperlipidemia, hypobetalipoproteinemia, Weber-Christian syndrome or abetalipoproteinemia
* on medication related to hepatic steatosis (tamoxifen, steroid, valproic acid, methotrexate, amiodarone)
* diabetes after pancreatectomy
* history of total parenteral nutrition in 6 months
* pregnancy or nursing mother
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeong Min Lee
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeong Min Lee, MD
Role: PRINCIPAL_INVESTIGATOR
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SNUH-2022-3238
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.